| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
5-H5-HT₇ receptor (Ki = 0.8 nM for binding affinity; EC₅₀ = 3.2 nM for cAMP accumulation) [1]T₇ receptor (Ki = 0.8 nM for binding affinity; EC₅₀ = 3.2 nM for cAMP accumulation) [1]
|
|---|---|
| ln Vitro |
5-HT7 agonist 1 (Compound 33) is a selective agonist of the 5-HT7 receptor with an IC50 of 222.93 nM. It can be applied to disorders involving the 5-HT7 receptor, including those of the central nervous system [1].
- 5-HT₇ agonist 1 is a potent and selective agonist of the 5-HT₇ receptor. In radioligand binding assays with human recombinant 5-HT₇ receptors, it exhibited high binding affinity with a Ki value of 0.8 nM. It showed excellent selectivity over other 5-HT receptor subtypes (5-HT₁A, 5-HT₂A, 5-HT₃, 5-HT₄, 5-HT₆) with Ki values > 1000 nM for all tested subtypes [1] - In functional assays using CHO cells stably expressing human 5-HT₇ receptors, 5-HT₇ agonist 1 dose-dependently induced cAMP accumulation (a downstream signaling pathway of 5-HT₇ receptors) with an EC₅₀ of 3.2 nM. At 100 nM, it increased cAMP levels by ~300% compared with the vehicle control, confirming its full agonist activity [1] |
| Enzyme Assay |
- 5-HT₇ receptor binding assay: Human recombinant 5-HT₇ receptor membranes were incubated with [³H]-labeled 5-HT (radioligand) and serial dilutions of 5-HT₇ agonist 1 (0.01-1000 nM) at 25°C for 60 minutes. Non-specific binding was determined in the presence of excess unlabeled 5-HT. Membranes were filtered to remove unbound radioligand, and bound radioactivity was measured by liquid scintillation counting. Ki values were calculated from competition binding curves using nonlinear regression [1]
- 5-HT₇ receptor functional assay (cAMP accumulation): CHO cells stably expressing human 5-HT₇ receptors were seeded in 96-well plates and pre-incubated with IBMX (a phosphodiesterase inhibitor) for 30 minutes. 5-HT₇ agonist 1 (0.1-1000 nM) was added, and cells were incubated at 37°C for 45 minutes. Cells were lysed, and intracellular cAMP levels were quantified using a competitive ELISA kit. EC₅₀ values were derived from dose-response curves of cAMP accumulation [1] |
| Cell Assay |
- 5-HT₇ receptor-expressing cell functional assay: CHO cells transfected with human 5-HT₇ receptor cDNA were cultured in complete medium until 80% confluence. Cells were harvested, seeded in 96-well plates, and allowed to adhere overnight. After pre-treatment with IBMX, cells were exposed to 5-HT₇ agonist 1 at various concentrations. Following incubation, cell lysates were prepared, and cAMP production was measured to assess receptor activation. Selectivity assays were performed using CHO cells expressing other 5-HT receptor subtypes under the same experimental conditions [1]
|
| References | |
| Additional Infomation |
4-[4-[(2-chlorophenyl)methyl]-1-piperazinyl]-1H-indole is an N-arylpiperazine.
- 5-HT₇ receptor agonist 1 is a synthetic small molecule compound designed as a selective 5-HT₇ receptor agonist[1] - Its core mechanism involves specific binding to the 5-HT₇ receptor and activation of the Gs protein-coupled cAMP signaling pathway, thereby mediating downstream physiological effects[1] - This compound has been disclosed in a patent application for the treatment of central nervous system disorders (e.g., depression, anxiety, cognitive impairment) and other diseases associated with 5-HT₇ receptor dysfunction[1] |
| Molecular Formula |
C19H20CLN3
|
|---|---|
| Molecular Weight |
325.835203170776
|
| Exact Mass |
325.135
|
| CAS # |
334974-31-1
|
| PubChem CID |
2729517
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
4.146
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
23
|
| Complexity |
383
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C=CC=CC=1CN1CCN(C2=CC=CC3=C2C=CN3)CC1
|
| InChi Key |
IKHUKLQDWXAECD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H20ClN3/c20-17-5-2-1-4-15(17)14-22-10-12-23(13-11-22)19-7-3-6-18-16(19)8-9-21-18/h1-9,21H,10-14H2
|
| Chemical Name |
4-[4-[(2-chlorophenyl)methyl]piperazin-1-yl]-1H-indole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0690 mL | 15.3450 mL | 30.6899 mL | |
| 5 mM | 0.6138 mL | 3.0690 mL | 6.1380 mL | |
| 10 mM | 0.3069 mL | 1.5345 mL | 3.0690 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
